TargetMol

Almotriptan Malate

Product Code:
 
TAR-T2317
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2317-10mg10mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2317-1mL1 mL * 10 mM (in DMSO)£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2317-25mg25mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2317-50mg50mg£181.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2317-100mg100mg£249.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2317-500mg500mg£515.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Almotriptan Malate, a selective 5-HT1B/1D receptor agonist, is used in the therapy of Migraine attacks in adults.
CAS:
181183-52-8
Formula:
C21H31N3O7S
Molecular Weight:
469.55
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9866
SMILES:
OC(CC(O)=O)C(O)=O.CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12
Target:
5-HT Receptor

References

1. Dodick, D. (2003). A review of the clinical efficacy and tolerability of almotriptan in acute migraine.?Expert Opinion On Pharmacotherapy,?4(7), 1157-1163. doi: 10.1517/14656566.4.7.1157 2. Fleishaker, J. (2000). Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers.?Clinical Pharmacology & Therapeutics,?67(5), 498-503. doi: 10.1067/mcp.2000.106292